Literature DB >> 30546900

Miliary lung metastases from non-small cell lung cancer with Exon 20 insertion: A dismal prognostic entity: A case report.

Akimasa Sekine1, Takuma Katano1, Tsuneyuki Oda1, Satoshi Ikeda1, Tae Iwasawa2, Hiroaki Satoh3, Toshiro Kataoka4, Koji Okudela4, Takashi Ogura1.   

Abstract

Miliary lung metastases have been reported to be frequently observed in nοn-small cell lung cancer (NSCLC) with major EGFR mutations, which consist of exon 19 deletion and exon 21 L858R. However, it remains undetermined whether NSCLC with minor EGFR mutations possesses characteristics similar to those with major EGFR mutations. In the present study, two cases of miliary lung metastases from NSCLC with exon 20 insertion were reported. Both the patients visited our hospital because of cough and/or dyspnea and were treated with chemotherapeutic agents, including platinum-doublet regimen. In addition, 1 patient received afatinib during the clinical course. However, all therapeutic regimens did not result in the desired outcome, and the respiratory condition rapidly deteriorated. Both the patients succumbed to disease within 3 months from the beginning of the 1st-line treatment due to disease progression. To conclude, chest physicians should be aware that miliary lung metastases could develop in NSCLC patients with exon 20 insertion and present a dismal prognosis.

Entities:  

Keywords:  exon 20 insertion; lung cancer; miliary metastases

Year:  2018        PMID: 30546900      PMCID: PMC6256252          DOI: 10.3892/mco.2018.1730

Source DB:  PubMed          Journal:  Mol Clin Oncol        ISSN: 2049-9450


  16 in total

1.  Miliary brain metastases in 2 cases with advanced non-small cell lung cancer harboring EGFR mutation during gefitinib treatment.

Authors:  Sayaka Mochizuki; Naoki Nishimura; Akira Inoue; Koji Murakami; Toshihiro Nukiwa; Naohiko Chohnabayashi
Journal:  Respir Investig       Date:  2012-07-15

Review 2.  EGFR exon 20 insertion mutations in non-small-cell lung cancer: preclinical data and clinical implications.

Authors:  Hiroyuki Yasuda; Susumu Kobayashi; Daniel B Costa
Journal:  Lancet Oncol       Date:  2011-07-19       Impact factor: 41.316

3.  Miliary never-smoking adenocarcinoma of the lung: strong association with epidermal growth factor receptor exon 19 deletion.

Authors:  Eckart Laack; Ronald Simon; Marc Regier; Birte Andritzky; Pierre Tennstedt; Christian Habermann; Christoph Zur Verth; Ina Thöm; Tobias Grob; Guido Sauter; Carsten Bokemeyer
Journal:  J Thorac Oncol       Date:  2011-01       Impact factor: 15.609

4.  Adenocarcinoma of the lung with miliary brain and pulmonary metastases with echinoderm microtubule-associated protein like 4-anaplastic lymphoma kinase translocation treated with crizotinib: a case report.

Authors:  Alexander T Falk; Michel Poudenx; Josiane Otto; Hannah Ghalloussi; Jérôme Barrière
Journal:  Lung Cancer       Date:  2012-09-19       Impact factor: 5.705

5.  Clinicopathological characteristics of 11 NSCLC patients with EGFR-exon 20 mutations.

Authors:  Marius Lund-Iversen; Lilach Kleinberg; Lars Fjellbirkeland; Åslaug Helland; Odd Terje Brustugun
Journal:  J Thorac Oncol       Date:  2012-09       Impact factor: 15.609

6.  Epidermal growth factor receptor exon 20 insertions in advanced lung adenocarcinomas: Clinical outcomes and response to erlotinib.

Authors:  M E Arcila; H A Yu; J Naidoo; C S Sima; K Rodriguez; N Busby; K Nafa; M Ladanyi; G J Riely; M G Kris
Journal:  Cancer       Date:  2015-06-10       Impact factor: 6.860

7.  Frequent EGFR mutations in nonsmall cell lung cancer presenting with miliary intrapulmonary carcinomatosis.

Authors:  Shang-Gin Wu; Fu-Chang Hu; Yih-Leong Chang; Yung-Chie Lee; Chong-Jen Yu; Yeun-Chung Chang; Jenn-Yu Wu; Jin-Yuan Shih; Pan-Chyr Yang
Journal:  Eur Respir J       Date:  2012-04-20       Impact factor: 16.671

8.  Rare EGFR exon 18 and exon 20 mutations in non-small-cell lung cancer on 10 117 patients: a multicentre observational study by the French ERMETIC-IFCT network.

Authors:  M Beau-Faller; N Prim; A-M Ruppert; I Nanni-Metéllus; R Lacave; L Lacroix; F Escande; S Lizard; J-L Pretet; I Rouquette; P de Crémoux; J Solassol; F de Fraipont; I Bièche; A Cayre; E Favre-Guillevin; P Tomasini; M Wislez; B Besse; M Legrain; A-C Voegeli; L Baudrin; F Morin; G Zalcman; E Quoix; H Blons; J Cadranel
Journal:  Ann Oncol       Date:  2013-11-26       Impact factor: 32.976

9.  Natural history and molecular characteristics of lung cancers harboring EGFR exon 20 insertions.

Authors:  Geoffrey R Oxnard; Peter C Lo; Mizuki Nishino; Suzanne E Dahlberg; Neal I Lindeman; Mohit Butaney; David M Jackman; Bruce E Johnson; Pasi A Jänne
Journal:  J Thorac Oncol       Date:  2013-02       Impact factor: 15.609

10.  Metastatic brain tumors from non-small cell lung cancer with EGFR mutations: distinguishing influence of exon 19 deletion on radiographic features.

Authors:  Akimasa Sekine; Terufumi Kato; Eri Hagiwara; Takeshi Shinohara; Takanobu Komagata; Tae Iwasawa; Hiroaki Satoh; Katsumi Tamura; Tomotaka Kasamatsu; Kenji Hayashihara; Takefumi Saito; Hiroshi Takahashi; Takashi Ogura
Journal:  Lung Cancer       Date:  2012-02-13       Impact factor: 5.705

View more
  3 in total

1.  Imaging Pattern of Diffuse Intrapulmonary Metastases in Lung Cancer Was Associated with Poor Prognosis to Epidermal Growth Factor Receptor Inhibitors.

Authors:  Yang Fu; Yuan Tang; Yue Zheng; Yue-Yun Chen; Ye Hong; Pei-Pei Wang; Qing Li; Ting Liu; Zhen-Yu Ding
Journal:  Cancer Manag Res       Date:  2020-11-17       Impact factor: 3.989

2.  Adenocarcinoma of the Lung Presenting with Intrapulmonary Miliary Metastasis.

Authors:  Saran Pillai; Adnan Khan; Sana Khan
Journal:  Cureus       Date:  2019-08-19

Review 3.  [Lung Adenocarcinomas with Pulmonary Miliary Metastases: A Case Report and Literature Review].

Authors:  Linxue Li; Liang Zhou; Jianyong Zhang
Journal:  Zhongguo Fei Ai Za Zhi       Date:  2019-12-20
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.